UK

May 10, 2018

UK Agency Recommends 3 New Blood Cancer Therapies, Including Adcetris for Lymphoma

News

The United Kingdom’s National Institute for Health and Care Excellence (NICE) recently recommended that three new blood cancer therapies be covered by the National Health Service (NHS) — Trisenox (arsenic trioxide), Rydapt ... Read more

April 24, 2018

Phase 2 ACCEPT Trial Explores Adding Acalabrutinib to Standard DLBCL Treatment

News

A Phase 2 clinical trial, ACCEPT, is designed to determine if adding acalabrutinib to standard, first-line R-CHOP chemotherapy will benefit patients with diffuse large B-cell lymphoma (DLBCL). The trial, ongoing ... Read more

February 13, 2018February 13, 2018

UK Agency Recommends Gazyvaro for First-Line Treatment of Follicular Lymphoma

News

The National Institute for Health and Care Excellence (NICE) in the United Kingdom has recommended Roche‘s Gazyvaro (obinutuzumab) as a first-line treatment for follicular lymphoma patients, after initially rejecting it. Routine use of ... Read more